Is H. pylori Infection the Missing Link in Obesity and Fatty Liver Disease?
"New research sheds light on the connection between H. pylori, obesity, and non-alcoholic fatty liver disease (NAFLD), offering potential insights for prevention and treatment."
The global rise in obesity and non-alcoholic fatty liver disease (NAFLD) has become a major public health concern. While factors like diet and lifestyle are known contributors, recent research suggests a potential link between Helicobacter pylori (H. pylori) infection and these metabolic disorders. This connection could offer new avenues for understanding, preventing, and treating these increasingly prevalent conditions.
NAFLD, affecting both lean and obese individuals, shares a common altered metabolic and cardiovascular profile, similar to that observed in traditional metabolic syndrome. This has prompted researchers to investigate underlying mechanisms, with H. pylori infection emerging as a potential player.
H. pylori, a bacterium commonly found in the stomach, has been linked to various health issues, including peptic ulcers and gastric cancer. However, its potential role in metabolic syndrome, insulin resistance, and related conditions like NAFLD is gaining increasing attention. Given the widespread prevalence of both H. pylori infection and metabolic syndrome, understanding this link could have significant implications for global health.
A Contested Association
Research on the relationship between Helicobacter pylori (H. pylori) infection and nonalcoholic fatty liver disease (NAFLD) remains unsettled. The cited studies and meta-analyses compare H. pylori-positive and H. pylori-negative patients, examining whether infection is associated with higher NAFLD risk. Some analyses report a positive correlation, while others describe conflicting or controversial results, so the current evidence does not establish H. pylori as a definitive cause of NAFLD.
Limits of Current Evidence
Assessment of a possible H. pylori-NAFLD connection generally depends on observational comparisons and meta-analyses. These approaches can identify associations, but they may not determine whether H. pylori infection contributes directly to liver disease or merely occurs alongside shared metabolic risk factors. Interpretation therefore requires caution, particularly when studies use different populations, diagnostic methods, and definitions of NAFLD.
An Evolving Research Question
The proposed connection between H. pylori infection and fatty liver disease has developed through observational research rather than a single definitive discovery. Early and subsequent studies produced mixed findings, prompting systematic reviews and meta-analyses to reassess the association. The field has consequently shifted from asking whether the conditions coexist to examining possible mechanisms and whether H. pylori treatment changes liver-related outcomes.
The H. pylori and Metabolic Syndrome Connection: Unpacking the Evidence
Evidence suggests a probable association between H. pylori infection and insulin resistance, a key feature of metabolic syndrome. This connection extends to various related morbidities, including NAFLD, abdominal obesity, type 2 diabetes mellitus, dyslipidemia, hypertension, and cardiovascular disease – the ultimate endpoint of metabolic syndrome.
- Impaired Ghrelin Production: H. pylori infection can impair gastric ghrelin production, a hormone that regulates appetite and energy balance.
- Increased Inflammation: Studies have shown that NAFLD patients with H. pylori infection have higher levels of anti-H. pylori IgG and tumor necrosis factor (TNF)-α, indicating increased inflammation.
- Cardiovascular Risk: H. pylori infection has been linked to increased levels of fibrinogen, an independent risk factor for cardiovascular disease.
Recent Evidence for a Two-Way Link
A 2024 meta-analysis reported evidence supporting a reciprocal relationship between H. pylori infection and susceptibility to NAFLD. It also identified associations involving body mass index, blood pressure, lipids, liver function, and kidney function. A prospective cohort study included 6,478 retired and active workers aged 22 to 69 years and collected measures including weight, waist circumference, BMI, blood pressure, fasting blood sugar, plasma lipids, and liver-function indicators. A 2025 systematic review and meta-analysis further examined whether H. pylori eradication affects clinical and laboratory parameters in patients with NAFLD, while noting that this correlation remains controversial.
Why Causation Remains Unproven
The association between H. pylori infection and NAFLD remains controversial, and similar uncertainty extends to metabolic dysfunction-associated fatty liver disease and related metabolic conditions. One 2023 meta-analysis reported that people with H. pylori infection had a 27.5% higher chance of developing NAFLD than those without the infection. However, the broader evidence base includes conflicting findings, so this figure should be interpreted as an association rather than proof that H. pylori causes NAFLD or liver fibrosis.
Comparing Association With Causation
The available research supports comparing H. pylori-positive and H. pylori-negative groups, but those comparisons do not automatically establish a causal pathway. Meta-analyses can strengthen the consistency of an observed association, yet their conclusions remain sensitive to differences in study design, diagnostic methods, and participant characteristics. The most defensible comparison is therefore between evidence suggesting an association and the still-limited evidence demonstrating that infection or eradication changes NAFLD outcomes.
The Potential Benefits of H. pylori Eradication
Eradicating H. pylori infection offers several potential benefits: it can decrease fibrinogen levels, increase high-density lipoprotein-cholesterol, decrease C-reactive protein levels, improve NAFLD fibrosis score and HSENSI (homocysteine, serum glutamic oxaloacetic transaminase, erythrocyte sedimentation rate, non-alcoholic steatohepatitis index), and improve homoeostatic model assessment and insulin resistance. By inhibiting prothrombotic and proinflammatory agents, H. pylori eradication might positively affect H. pylori-related NAFLD and CVD development/progression and benefit metabolic syndrome-related morbidity. These findings suggest that H. pylori infection as a risk factor for NAFLD, appears to be a common denominator underlying the shared altered metabolic syndrome and cardiovascular profile between lean and obese patients. Its eradication might benefit the aforementioned profile, and these findings merit further investigation.
A Possible Link, Not a Verdict
Taken together, the research suggests that H. pylori may be connected with NAFLD and broader metabolic dysfunction, but the relationship is not settled. Reported associations with BMI, blood pressure, lipids, and liver-function measures make the question biologically relevant. At present, the evidence supports further investigation rather than treating H. pylori as the established missing link in obesity or fatty liver disease.
Testing the Treatment Question
Future research needs to clarify whether H. pylori eradication changes the development or severity of NAFLD. Prospective cohorts with standardized measurements could help separate infection-related effects from background metabolic risk. Systematic reviews of eradication studies may also determine whether treatment produces meaningful improvements in clinical or laboratory outcomes.
A Global, Multifactorial Problem
H. pylori infection and NAFLD are both recognized as conditions that affect human health globally. A 2023 mini-review evaluated their epidemiology, possible pathogenesis, and the evidence for H. pylori infection as a modifiable risk factor in preventing or treating NAFLD. Its framing reflects the central challenge: the infection may be relevant, but the association remains unclear and must be considered alongside the broader metabolic context.
Cautious Clinical Interpretation
For patients, uncertainty about the H. pylori-NAFLD relationship means that a positive infection test should not automatically be presented as the explanation for obesity or fatty liver disease. Conversely, the unresolved association warrants attention when clinicians evaluate gastrointestinal infection alongside metabolic and liver findings. Decisions should remain grounded in established clinical assessment while research continues to determine whether treating H. pylori changes long-term liver outcomes.